Kyverna Therapeutics, Inc.
General ticker "KYTX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $457.2M (TTM average)
Kyverna Therapeutics, Inc. follows the US Stock Market performance with the rate: 30.4%.
Estimated limits based on current volatility of 2.7%: low 6.88$, high 7.27$
Factors to consider:
- Total employees count: 130 (+16.1%) as of 2025
- Top business risk factors: Limited operating history, No approved products, Net losses, Regulatory and compliance, Clinical trial delays
- Price in estimated range
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [4.65$, 13.04$]
- 2026-12-31 to 2027-12-31 estimated range: [2.79$, 8.37$]
Short-term KYTX quotes
Long-term KYTX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $62.41MM | $142.60MM | $169.83MM |
| Operating Income | $-62.41MM | $-142.60MM | $-169.83MM |
| Non-Operating Income | $2.04MM | $15.13MM | $8.52MM |
| Interest Expense | $0.19MM | $0.14MM | $0.49MM |
| R&D Expense | $49.92MM | $112.47MM | $133.72MM |
| Income(Loss) | $-60.37MM | $-127.48MM | $-161.31MM |
| Net Income(Loss)* | $-60.37MM | $-127.48MM | $-161.31MM |
| Stockholders Equity | $-131.40MM | $266.59MM | $232.28MM |
| Assets | $75.19MM | $304.64MM | $293.83MM |
| Operating Cash Flow | $-52.41MM | $-114.25MM | $-153.71MM |
| Capital expenditure | $0.62MM | $2.21MM | $0.01MM |
| Investing Cash Flow | $-8.79MM | $-160.90MM | $40.02MM |
| Financing Cash Flow | $58.12MM | $337.11MM | $141.17MM |
| Earnings Per Share** | $-0.09 | $-3.33 | $-3.64 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.